Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) and Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Profitability
This table compares Cyclerion Therapeutics and Vanda Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclerion Therapeutics | N/A | -55.32% | -48.35% |
| Vanda Pharmaceuticals | -8.59% | -3.02% | -2.52% |
Earnings & Valuation
This table compares Cyclerion Therapeutics and Vanda Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclerion Therapeutics | $1.62 million | 7.11 | -$5.26 million | N/A | N/A |
| Vanda Pharmaceuticals | $192.64 million | 1.42 | $2.51 million | ($0.28) | -16.75 |
Risk and Volatility
Cyclerion Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Cyclerion Therapeutics and Vanda Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclerion Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
| Vanda Pharmaceuticals | 0 | 0 | 2 | 0 | 3.00 |
Vanda Pharmaceuticals has a consensus price target of $15.50, indicating a potential upside of 230.49%. Given Vanda Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than Cyclerion Therapeutics.
Insider and Institutional Ownership
75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 36.1% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 8.9% of Vanda Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Vanda Pharmaceuticals beats Cyclerion Therapeutics on 8 of the 12 factors compared between the two stocks.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company’s pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
